Asunto(s)
Enfermedades Óseas Metabólicas/patología , Linfoma de Células B de la Zona Marginal/diagnóstico , Linfoma Cutáneo de Células T/patología , Osificación Heterotópica/patología , Enfermedades Cutáneas Genéticas/patología , Neoplasias Cutáneas/patología , Enfermedades Óseas Metabólicas/diagnóstico , Enfermedades Óseas Metabólicas/etiología , Rojo Congo/metabolismo , Femenino , Humanos , Linfoma de Células B de la Zona Marginal/complicaciones , Persona de Mediana Edad , Osificación Heterotópica/diagnóstico , Osificación Heterotópica/etiología , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/etiología , Coloración y Etiquetado/métodos , Sindecano-1/metabolismoRESUMEN
PURPOSE OF REVIEW: The most recent recommendations for the management of both acute (ARS) and chronic rhinosinusitis (CRS) based on the strongest data available for each treatment modality are summarized in this review. The clinical relationships between CRS and its comorbidities are also discussed. RECENT FINDINGS: The most promising advances in rhinosinusitis management involve the use of mAbs (anti-IgE, anti-IL-5, anti-IL-4Rα) in trials of CRS with nasal polyposis. Otherwise, the mainstays of treatment for both ARS and CRS have largely remained the same over the past several years. SUMMARY: The treatment of ARS primarily involves symptomatic control with intranasal corticosteroids and nasal saline irrigation; antibiotics should be reserved for the patients who are believed to have bacterial rhinosinusitis. Treating CRS effectively involves using intranasal corticosteroids and irrigation, systemic corticosteroids, and potentially systemic antibiotics. Biologics (mAbs) have shown benefit in clinical studies. Providers should also be aware of concomitant disease processes that may afflict patients with CRS.